The Anhui Medical Centralized Procurement Platform has issued a notice, officially initiating the centralized procurement process for biological drugs. This initiative encompasses eight monoclonal antibody biopharmaceuticals, including adalimumab and bevacizumab, within a market segment totaling nearly 30 billion yuan. Given the intense competition in this sector, Anhui is spearheading this procurement effort to assess the current landscape of the biopharmaceutical industry and evaluate the capacity of enterprises, thereby furnishing essential data for future policy development.